Gastric inhibitory polypeptide: the neglected incretin revisited (Q34758871)

4 August 2017

1 reference

title

Gastric inhibitory polypeptide: the neglected incretin revisited (English)

1 reference

4 August 2017

4

Baptist Gallwitz

0 references

author name string

Juris J Meier

series ordinal

1

1 reference

4 August 2017

Michael A Nauck

series ordinal

2

1 reference

4 August 2017

Wolfgang E Schmidt

series ordinal

3

1 reference

4 August 2017

1 July 2002

1 reference

4 August 2017

1 reference

4 August 2017

107

1 reference

4 August 2017

1-3

1 reference

4 August 2017

1-13

1 reference

On the treatment of Diabetus mellitus by acid extract of Duodenal Mucous Membrane

4 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Stimulation of release of insulin by an extract of intestinal mucosa

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Further purification of a polypeptide demonstrating enterogastrone activity

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

A Gastric Inhibitory Polypeptide II: The Complete Amino Acid Sequence

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Effect of gastric inhibitory polypeptide on pentagastrin-stimulated acid secretion in man

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

PLASMA INSULIN RESPONSE TO ORAL AND INTRAVENOUS GLUCOSE ADMINISTRATION

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Intestinal Factors in the Control of Insulin Secretion

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

The insulinotropic action of gastric inhibitory polypeptide in the perfused isolated rat pancreas

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Interaction of gastric inhibitory polypeptide, glucose, and arginine on insulin and glucagon secretion from the perfused rat pancreas

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Stimulation of insulin secretion by gastric inhibitory polypeptide in man

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Oral glucose augmentation of insulin secretion. Interactions of gastric inhibitory polypeptide with ambient glucose and insulin levels

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

The incretin concept today

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

New developments in the incretin concept

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

The effect of endogenous gastric inhibitory polypeptide on glucose-induced insulin secretion in mild diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Effect of porcine gastric inhibitory polypeptide on beta-cell function in type I and type II diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Effects of intravenously infused porcine GIP on serum insulin, plasma C-peptide, and pancreatic polypeptide in non-insulin-dependent diabetes in the fasting state.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Glucose dependent insulinotropic polypeptide (GIP) infused intravenously is insulinotropic in the fasting state in type 2 (non-insulin dependent) diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

chimeric peptides define the structural requirements for specific ligand-receptor interaction of GLP-1

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Cellular localization of gastric inhibitory polypeptide in the duodenum and jejunum

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Identification of the intestinal cell storing gastric inhibitory peptide

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Electronimmunocytochemical evidence for the K cell localization of gastric inhibitory polypeptide (GIP) im man

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Glucagon-Like Peptides GLP-1 and GLP-2, Predicted Products of the Glucagon Gene, Are Secreted Separately from Pig Small Intestine but Not Pancreas*

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Colocalization of GLP-1 and GIP in human and porcine intestine

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Gastric inhibitory polypeptide (GIP) stimulation by oral glucose in man

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Gastric Inhibitory Polypeptide (GIP) Stimulated by Fat Ingestion in Man

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Glucose-dependent insulin release from genetically engineered K cells

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Immunocytochemical evidence for a paracrine interaction between GIP and GLP-1-producing cells in canine small intestine

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Commercially available preparations of porcine glucose-dependent insulinotropic polypeptide (GIP) contain a biologically inactive GIP-fragment and cholecystokinin-33/-39

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Investigation of glucose-dependent insulinotropic polypeptide-(1-42) and glucagon-like peptide-1-(7-36) degradation in vitro by dipeptidyl peptidase IV using matrix-assisted laser desorption/ionization-time of flight mass spectrometry. A novel [...]

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Amino acid sequence and heterogeneity of gastric inhibitory polypeptide (GIP)

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

The pharmacokinetics of porcine glucose-dependent insulinotropic polypeptide (GIP) in man

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Insulinotropic properties of synthetic human gastric inhibitory polypeptide in man: interactions with glucose, phenylalanine, and cholecystokinin-8

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Improved glucose tolerance in rats treated with the dipeptidyl peptidase IV (CD26) inhibitor Ile-thiazolidide

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Chronic renal failure: effect of hemodialysis on gastrointestinal hormones.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Renal effects on serum gastric inhibitory polypeptide (GIP).

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

All products of proglucagon are elevated in plasma from uremic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Removal of IR-GIP by the Kidneys in Man, and the Effect of Acute Nephrectomy on Plasma GIP in Rats

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

The hepatic extraction of gastric inhibitory polypeptide and insulin.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Absence of hepatic extraction of gastric inhibitory polypeptide in conscious dogs

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Impaired feedback control of fat induced gastric inhibitory polypeptide (GIP) secretion by insulin in obesity and glucose intolerance

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Gastric inhibitory polypeptide (GIP) and insulin in obesity: Increased response to stimulation and defective feedback control of serum levels

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Gastric inhibitory polypeptide release after oral glucose: relationship to glucose intolerance, diabetes mellitus, and obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Gastric Inhibitory Polypeptide in Obesity and Diabetes Mellitus*

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Gastric inhibitory polypeptide responses and glucose turnover rates after natural meals in type II diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Gastric inhibitory polypeptide responses to nutrients in Caucasians and American Indians with obesity and noninsulin-dependent diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Immunoreactive gastric inhibitory polypeptide

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Gastric inhibitory polypeptide enhancement of the insulin effect on fatty acid incorporation into adipose tissue in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Effect of the entero-pancreatic hormones, gastric inhibitory polypeptide and glucagon-like polypeptide-1(7-36) amide, on fatty acid synthesis in explants of rat adipose tissue

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Inhibition of actions of glucagon in adipocytes by gastric inhibitory polypeptide

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Effects of gastric inhibitory polypeptide on glucose and lipid metabolism of isolated rat adipocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Gastric inhibitory polypeptide receptor, a member of the secretin- vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Functional GIP receptors are present on adipocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Effect of gastric inhibitory polypeptide on plasma levels of chylomicron triglycerides in dogs

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Effect of endogenous gastric inhibitory polypeptide (GIP) on the removal of triacylglycerol in dogs

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Effect of Exogenous or Endogenous Gastric Inhibitory Polypeptide (GIP) on Plasma Triglyceride Responses in Rats

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Response of adipose tissue lipoprotein lipase activity and serum lipoproteins to acute hyperinsulinaemia in man

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Lack of effect of exogenous or endogenous gastric inhibitory polypeptide on the elimination rate of Intralipid in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Lack of effect of synthetic human gastric inhibitory polypeptide and glucagon-like peptide 1 [7-36 amide] infused at near-physiological concentrations on pentagastrin-stimulated gastric acid secretion in normal human subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Gut hormones and diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Comparison of the effect of GIP and GLP-1 (7-36amide) on insulin release from rat pancreatic islets

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Glucagon-like peptide-1 7-36: a physiological incretin in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

The effects of glucose-dependent insulinotropic polypeptide infused at physiological concentrations in normal subjects and Type 2 (non-insulin-dependent) diabetic patients on glucose tolerance and B-cell secretion

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Depression of insulin release by anti-GIP serum after oral glucose in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Postprandial stimulation of insulin release by glucose-dependent insulinotropic polypeptide (GIP). Effect of a specific glucose-dependent insulinotropic polypeptide receptor antagonist in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Glucose-dependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signaling

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Reduced incretin effect in type 2 (non-insulin-dependent) diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Stimulation of glucagon secretion by gastric inhibitory polypeptide in patients with hepatic cirrhosis and hyperglucagonemia

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Glucose-dependent insulinotropic hormone potentiates the hypoglycemic effect of glibenclamide in healthy volunteers: evidence for an effect on insulin extraction

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Role of Regulator of G Protein Signaling in Desensitization of the Glucose-Dependent Insulinotropic Peptide Receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

The cysteine of the cytoplasmic tail of glucose-dependent insulinotropic peptide receptor mediates its chronic desensitization and down-regulation

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Role of glucose in chronic desensitization of isolated rat islets and mouse insulinoma (betaTC-3) cells to glucose-dependent insulinotropic polypeptide.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2-diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Gut hormones as pharmaceuticals. From enteroglucagon to GLP-1 and GLP-2.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

The pathogenesis of NIDDM involves a defective expression of the GIP receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Discovery of amino acid variants in the human glucose-dependent insulinotropic polypeptide (GIP) receptor: the impact on the pancreatic beta cell responses and functional expression studies in Chinese hamster fibroblast cells

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Characterisation of beta-cell dysfunction of impaired glucose tolerance: evidence for impairment of incretin-induced insulin secretion.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

The role of impaired early insulin secretion in the pathogenesis of Type II diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37).

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Insulinotropic action of glucagonlike peptide-I-(7-37) in diabetic and nondiabetic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

A role for glucagon-like peptide-1 in the central regulation of feeding

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Intraventricular GLP-1 reduces short- but not long-term food intake or body weight in lean and obese rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Repeated intracerebroventricular administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters body weight in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Inhibition of dipeptidyl peptidase IV by fluoroolefin-containing N-peptidyl-O-hydroxylamine peptidomimetics

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

The entero-insular axis in type 2 diabetes--incretins as therapeutic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Amino terminal glycation of gastric inhibitory polypeptide enhances its insulinotropic action on clonal pancreatic B-cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

NH2-terminally modified gastric inhibitory polypeptide exhibits amino-peptidase resistance and enhanced antihyperglycemic activity.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Improved glycaemic control in obese diabetic ob/ob mice using N-terminally modified gastric inhibitory polypeptide

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Modulation of glucose responsiveness of insulinoma beta-cells by graded overexpression of glucokinase

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Reversal of insulin-dependent diabetes using islets generated in vitro from pancreatic stem cells

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Current perspectives of biotechnological replacement of insulin secreting cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Regulated hepatic insulin gene therapy of STZ-diabetic rats

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

Inhibitory effect of glucagon-like peptide-1 on small bowel motility. Fasting but not fed motility inhibited via nitric oxide independently of insulin and somatostatin

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900039-3

7 January 2021

10.1016/S0167-0115(02)00039-3

Identifiers

DOI

1 reference

release_ummqjfatkfeinlhm5i3d4q73ge

4 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ummqjfatkfeinlhm5i3d4q73ge

24 November 2022

mapped directly with Wikidata item

1 reference